CompletedNot Applicable

Intraventricular Stasis In Cardiovascular Disease

Spain258 participantsStarted 2020-11-24

Plain-language summary

This study is designed to quantify the ventricular stasis in patients with different forms of cardiomyopathy and at risk of stroke (ischemic, non-ischemic dilated cardiomyopathy and hypertrophic cardiomyopathy) by post-processing of 2D color Doppler echocardiography and phase contrast-magnetic resonance images in order to establish the relationship between quantitative variables of intraventricular stasis and the prevalence of silent embolic events and/or intraventricular mural thrombosis.

Who can participate

Age range

18 Years – 100 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 years of age. * Sinus rhythm. * Meet one of the following criteria: * Diagnosis of non ischemic DCM and ejection fraction (EF) of LV less than 45% * Diagnosis of ischemic DCM and ejection fraction (EF) of LV less than 45% * Diagnosis of hypertrofic myocardiophathy and ejection fraction (EF) of LV less than 55% or apical aneurism diagnosed in an image test. Exclusion Criteria: * Implantable defibrillation or stimulation devices not compatible with MRI. * Hemodinamically significant heart valve disease or prosthetic heart valves. * Claustrophobia. * Persistent of paroxysmal atrial fibrillation (AF). * Prior history of significant carotid disease with stenosis greater than 50%. * Full anticoagulation therapy prior to admission or indication of anticoagulation. * Pro-thrombotic disorders (active oncology disease, coagulation disorders…)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Prevalence of a combined binary variable consisting of ventricular thrombosis or silent brain infarct detected by magnetic resonance

Timeframe: Within 10 days after enrollment

Trial details

NCT IDNCT04649034

SponsorHospital General Universitario Gregorio Marañon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Dilated Cardiomyopathy trials